Sun Pharma has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 2 of them, and has 4 filed or in development. Those brands earned $43.2B in 2025. Of the 70 makers we follow, 12 are lined up to copy more of these drugs.
| Drug | Sun Pharma's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 31 Aug 2026 | 4 on sale · 5 approvedof 10 other makers listed | $2.7B |
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 26 Aug 2025 | 2 on sale · 9 approvedof 11 other makers listed | $2.3B |
| Drug | Sun Pharma's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| VraylarGeneric · AbbVie · US LOE 2029 | FDA-approved 30 Sep 2022, not marketed | 0 on sale · 0 approvedof 2 other makers listed | $3.6B |
| Drug | Sun Pharma's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| JakafiGeneric · Incyte · US LOE 2028 | Filed with the FDA; in litigation | 0 on sale · 0 approvedof 9 other makers listed | $3.1B |
| Invega SustennaGeneric · Johnson & Johnson · US LOE 2031 | Filed with the FDA; settled Dec 2025 | 0 on sale · 0 approvedof 3 other makers listed | $3.8B |
| OzempicGeneric · Novo Nordisk · US LOE 2032 | Filed with the FDA; settled, terms confidential | 0 on sale · 1 approvedof 6 other makers listed | ≈$19.3B |
| RinvoqGeneric · AbbVie · US LOE 2037 | Filed with the FDA; settled Sep 2025; US entry allowed from Apr 2037. Assuming pediatric exclusivity is granted | 0 on sale · 0 approvedof 4 other makers listed | $8.3B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Sun Pharma sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Sun Pharma's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Sun Pharma's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Stock Analysis.